Clinical Trials
64 trialsSIGHER
Centre Paul Strauss
Pilot Study on the Clinical Efficacy of Focused Ultrasound-Mediated Targeted Drug Delivery System Combined With Neoadjuvant Therapy for HER2-Positive Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
Fox Chase Cancer Center
Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy
University of Washington
HERO
NRG Oncology
Tumor-microenvironment Spatial Interaction to Identify Markers of Resistance to Therapy in HER2+ Breast Cancer Patients
IRCCS Ospedale San Raffaele
Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer
Peking University Cancer Hospital & Institute
Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging
University of Alabama at Birmingham
Traderrus
Blokhin's Russian Cancer Research Center
BREASTIMMU02
Centre Leon Berard
ANISE
The Netherlands Cancer Institute
Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer
University of Rochester
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
Fudan University
Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer
National Cancer Centre, Singapore
Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer
Shaanxi Provincial Cancer Hospital
FastER
University of Miami
HER2-DM-NACT
Hebei Medical University Fourth Hospital
A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)
Fudan University
Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study
Hebei Medical University Fourth Hospital
Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
University of Alabama at Birmingham
Omission of Radiation in Patients With Her-2 Positive Breast Cancer
University of Kansas Medical Center
TUC-TOC
Institut Curie
Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)
First Affiliated Hospital of Zhejiang University
GeparPiPPa
GBG Forschungs GmbH
Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC
Fujian Medical University Union Hospital
Pyrotinib in HER2-positive Early Breast Cancer
Yunnan Cancer Hospital
LRNacHER2
Peking University People's Hospital
TaxCbHER2
Peking University People's Hospital
TaxHER
Peking University People's Hospital
TaxDHER2
Peking University People's Hospital
NacHER2
Peking University People's Hospital
NeraHER2
Peking University People's Hospital
nonPHER
Peking University People's Hospital
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
Shengjing Hospital
T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer
Fudan University
A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
Shengjing Hospital
The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
Samsung Medical Center
Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
University of Kansas Medical Center
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
Hebei Medical University Fourth Hospital
Real World Patient-Reported Outcomes in Chinese Her2+ EBC Patients Receiving (Neo) Adjuvant Anti-Her2 Based Therapy
Fudan University
A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Pyrotinib in Women With High-risk in Early Stage Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Thero2-01S22 in HER2-positive Breast Cancer
Institut de cancérologie Strasbourg Europe
HERdi PREDICT
King's College London
Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer
Hunan Cancer Hospital
Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038
First Affiliated Hospital Xi'an Jiaotong University
PHARE-C
Institut de cancérologie Strasbourg Europe
Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
HERMET
University of Kansas Medical Center
Affibody-3
Uppsala University Hospital